Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacokinetics of cyclophosphamide.

Literature DB >> 389529

Clinical pharmacokinetics of cyclophosphamide.

L B Grochow, M Colvin.

Abstract

Entities: Chemical

Mesh：

Substances：
Cyclophosphamide

Year: 1979 PMID： 389529 DOI： 10.2165/00003088-197904050-00004

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

49 in total

1. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors: R F Struck; M C Kirk; M H Witt; W R Laster
Journal: Biomed Mass Spectrom Date: 1975-02

2. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

Authors: C Fenselau; M N Kan; S S Rao; A Myles; O M Friedman; M Colvin
Journal: Cancer Res Date: 1977-08 Impact factor: 12.701

3. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors: J L Cohen; J Y Jao
Journal: J Pharmacol Exp Ther Date: 1970-08 Impact factor: 4.030

4. Alopecia activity of cyclophosphamide metabolites and related compounds in sheep.

Authors: V J Feil; C H Lamoureux
Journal: Cancer Res Date: 1974-10 Impact factor: 12.701

5. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Authors: H T Mouridsen; O Faber; L Skovsted
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1974-08

6. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors.

Authors: G M Mullins; M Colvin
Journal: Cancer Chemother Rep Date: 1975 Mar-Apr

7. Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide.

Authors: H T Mouridsen; J Witten; P L Frederiksen; I Hulsbaek
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1978-10

8. Alkylating properties of phosphoramide mustard.

Authors: M Colvin; R B Brundrett; M N Kan; I Jardine; C Fenselau
Journal: Cancer Res Date: 1976-03 Impact factor: 12.701

9. Effect of phenobarbital on cyclophosphamide cytotoxic activity and pharmacokinetics in mice.

Authors: M G Donelli; A Vecchi; A Bossi; T Colombo; M Sironi; C Pantarotto; S Garattini; F Spreafico
Journal: Tumori Date: 1977 Mar-Apr

10. Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.

Authors: D S Alberts; Y M Peng; H S Chen; R F Struck
Journal: Br J Cancer Date: 1978-08 Impact factor: 7.640

26 in total

Review 1. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors: Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal: Clin Pharmacokinet Date: 2004 Impact factor: 6.447

2. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Authors: Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis
Journal: Drugs Aging Date: 2005 Impact factor: 3.923

Clinical pharmacokinetics of cyclophosphamide.

1. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

2. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

3. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

4. Alopecia activity of cyclophosphamide metabolites and related compounds in sheep.

5. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

6. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors.

7. Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide.

8. Alkylating properties of phosphoramide mustard.

9. Effect of phenobarbital on cyclophosphamide cytotoxic activity and pharmacokinetics in mice.

10. Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.

Review 1. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

2. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Review 3. Antineoplastic drugs in 1990. A review (Part II).

Review 4. Optimisation of cyclophosphamide therapy in systemic vasculitis.

Review 5. Guide to drug dosage in renal failure.

Review 6. Pharmacokinetic drug interactions of commonly used anticancer drugs.

Review 7. Limited-sampling models for anticancer agents.

Review 8. Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

9. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

10. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.